ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Press Release Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Clinical Development Program for Multiple Indications
December 03, 2021Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the selection of PN-235 (JNJ-77242113) as the final candidate for all clinical studies in multiple indications based on intervention of the Interleukin-23 (IL-23)...
Pharma Sources Insight January 2025
